Skip to content
Apex Flow

Plan policy, Cigna, commercial plans

What Cigna's published policy says about Skyrizi (risankizumab-rzaa)

The documents Cigna publishes for Skyrizi, linked to the plan's own pages, and what those documents list. Read through the free KAIS guide on November 4, 2026 for commercial plans; these are the documents the guide returns in each of the ten states checked: Arizona, California, Florida, Georgia, Illinois, New York, North Carolina, Ohio, Pennsylvania and Texas.

What the policy lists

Prior authorizationlisted in the policy

Cigna's documents for Skyrizi

What your plan's policy says

The plan's document holds the details for this medicine.

What this medicine is used for

“SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.”

“active psoriatic arthritis in adults and pediatric patients 6 years of age and older.”

“moderately to severely active ulcerative colitis in adults.”

“Plaque Psoriasis SKYRIZI ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.”

“Psoriatic Arthritis SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older.”

“Ulcerative Colitis SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.”

From the FDA label for Skyrizi, revised June 15, 2026. The label is shown in English as published. DailyMed. Your doctor decides what it is used for in your case.

Common questions

Does Cigna require prior authorization for Skyrizi?

Cigna's published policy lists prior authorization for Skyrizi.

How do I see the policy for my own plan and state?

Open the free KAIS guide, pick your plan, your type of plan, your state and your medicine, and it shows the policy your plan publishes, with the link to the plan's own document.

Not medical advice and not a decision on your claim. Your doctor and your plan decide.